TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Bronchoscopy With Bronchoalveolar Lavage in Identifying Biomarkers of Response to Immune Checkpoint Inhibitors in Patients With Non-small Cell or Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC)~* Candidate to undergo immune checkpoint inhibitor (ICI) therapy for SCLC or NSCLC (ICI as any line of chemotherapy is acceptable) as deemed by individual's treating oncologist~* Enrollment into this study may occur in tandem with other clinical therapeutics trials occurring at Vanderbilt University Medical Center (VUMC) as long as this trial does not violate protocol or inclusion criteria of that study~Exclusion Criteria:~* Coagulopathy with international normalized ratio (INR) \> 2.0 or~* Coagulopathy with platelets (Plt) \< 10 k~* Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)~* Subjects with an active or recent history of a known or suspected autoimmune disease or recent history of a syndrome that required systemic corticosteroids/immunosuppressive medications~* Respiratory failure requiring greater than 6 Lpm supplemental oxygen (O2) by nasal cannula or mechanical ventilation within the past six weeks~* Inability to perform informed consent due to any medical or psychiatric condition

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bronchoscopy with bronchoalveolar lavage (Type: EXPERIMENTAL): Patients undergo bronchoscopy with bronchoalveolar lavage over 45 minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Longitudinal Study of Traumatic Brain Injury (TBI) in (University of Florida) UF Athletes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Currently enrolled and active UF student athlete in Mens Football, Womens Soccer, or Womens Lacrosse.~* Age 18-30~Exclusion Criteria:~* Contraindications to MRI, such as retained metal~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Magnetic Resonance Imaging (MRI) (Type: OTHER): Athletes at risk for mild traumatic brain injury during the course of competitive play or practice. An MRI will be obtained at study entry, following any TBI occuring during sanctioned practice or play, and at study exit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness of Agilus (Hyaluronic Acid) for Ankle Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older~* Chronic, unilateral ankle pain(i.e., in only one ankle) for at least 6 months~* Diagnosis of ankle OA confirmed by radiographs (X-ray)and clinical exam~* Are normally active, without aid of mobility devices(such as crutch, walker or cane)~Exclusion Criteria:~* Have used oral steroids within 30 days (inhaled or topical steroids are acceptable)~* Have received intra-articular injections of hyaluronic acid in any joint in the last 9 months~* Have received steroid injections in any joint in last 3 months~* Have had previous surgery or arthroscopy on the affected ankle in the last 12 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Active (Type: ACTIVE_COMPARATOR): Agilus (Hyaluronic Acid)
- Control (Type: PLACEBO_COMPARATOR): Normal Saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Stellate Ganglion Block: A Breakthrough Treatment for Post-Stroke Pharyngeal Dysphagia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 30 and 80 years;~* New-onset stroke, confirmed by head CT or MRI;~* The course of disease between 1 to 6 months;~* With pharyngeal dysphagia shown by VFSS;~* Stable vital signs;~* Voluntary participation in the study.~Exclusion Criteria:~* Allergy to Lidocaine injection or vitamin B12 injection;~* Severe cognitive impairment;~* Coagulation disorders;~* Severe dysfunction of organs including heart, lungs, kidney, liver, etc.;~* Complicated with other neurological diseases;~* With severe oral dysphagia (results of the VFSS oral phase as 2 or 3 points);~* Dysphagia caused by other diseases or reasons.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- The observation group (Type: EXPERIMENTAL): Patients enrolled were firstly numbered for privacy with software and divided into the observation group (n=33) and the control group (n=33) with a random number table. Additionally, the staffs involved in assessment would not participate in the intervention of the study. The treatment lasted 20 days.
- The control group (Type: ACTIVE_COMPARATOR): Patients enrolled were firstly numbered for privacy with software and divided into the observation group (n=33) and the control group (n=33) with a random number table. Additionally, the staffs involved in assessment would not participate in the intervention of the study. The treatment lasted 20 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing EBUS & EUS to Mediastinoscopy in Staging and Detection of Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 21 years or greater~* Pt is a surgical candidate for mediastinoscopy, thoracoscopy, or lung resection~* Known or suspected non-small cell carcinoma of the lung eligible for resection~* CT scan performed within 45 days prior to evaluation for study participation~* PET scan performed within 45 days prior to evaluation for study participation~Exclusion Criteria:~* Pathologically proven metastatic disease~* History of malignancy within 5 years other than (skin) basal cell carcinoma~* Enlarged ipsilateral mediastinal lymph nodes \> 2.5 cm in diameter~* Peripheral T1 tumors with normal mediastinal lymph nodes on CT and PET

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- traditional mediastinoscopy/thoracoscopy (Type: ACTIVE_COMPARATOR): Traditional Mediastinoscopy used to detect or stage lung cancers.
- EBUS/EUS (Type: ACTIVE_COMPARATOR): Minimal invasive technique for staging/detecting lung cancer.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Persona MC vs Attune Total Knee Replacement Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Aged 18 years and above\*~2. Have undergone primary total knee replacement for either:~   1. Osteoarthritis~  2. avascular necrosis of the femur or tibia~3. Report an Oxford Knee Score greater than 34, obtained from usual clinical practice. OKS above 34 represents (range 0-48, high representing good outcome) a good outcome post-surgery.~4. Independent of study participation, patients received either commercially available Zimmer Biomet Persona MC bearing or DePuy Synthes Attune knee implants implanted in accordance with product labelling~5. 1-5 years post TKR surgery~6. An adequate understanding of written and verbal information in English in order to provide informed consent and answer the study questionnaires\* \* Control participants will meet same inclusion criteria except no primary TKR and OKS will not be required~Exclusion Criteria:~1. History of infection in the replaced joint and/or other local/systemic infection that may affect the prosthetic joint~2. Skeletal immaturity~3. Neuropathic arthropathy~4. Osteoporosis/any loss of musculature or neuromuscular disease that compromises the affected limb~5. Severe instability secondary to the absence of collateral ligament integrity~6. Pregnancy - routine clinical practice ensures that all female patients are asked whether they are pregnant and can safely receive x-rays or surgery as per standard consent forms~7. Patient is a member of a protected population (e.g., prisoner, mentally incompetent, etc.)~8. Patient has previously received partial or total knee arthroplasty for the ipsilateral knee~9. Patients who are unable to give voluntary informed consent.~10. Patients who are unable to walk unaided (post-surgery).~11. BMI \> 40~    \*\* Control participants will meet the same exclusion criteria as TKR patients~12. Patients who suffer with cognitive impairment such as Parkinson's or Alzheimer's disease resulting in impaired mental capacity.~13. Patients who are unable to walk unaided.~14. Patients who suffer from dizzy spells or fainting episodes.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Persona TKR (Type: None): Patients will have undergone a medial congruent Persona total knee replacement
- Attune TKR (Type: None): Patients will have undergone a Attune total knee replacement
- Control participants (Type: None): Patients will not have recieved a primary TKR

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed stage IV non-small cell lung cancer that cannot be cured with existing therapeutic regimens~* Measurable disease by CT scan or MRI~  * Tumor must be at least 2 cm for the lymph nodes located in the head, neck, axillary, inguinal or femoral areas and at least 0.5 cm for other areas~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status~* Karnofsky 60-100%~Life expectancy:~* At least 2 months~Hematopoietic:~* WBC at least 2,000/mm\^3~* Platelet count at least 50,000/mm\^3~Hepatic:~* No hepatic insufficiency~* Bilirubin no greater than 2.5 mg/dL~* SGOT and SGPT no greater than 5 times upper limit of normal~Renal:~* No renal insufficiency~* Creatinine no greater than 2.5 mg/dL~Cardiovascular:~* No chronic heart failure~* No uncontrolled hypertension~Pulmonary:~* No serious lung disease (e.g., severe chronic obstructive pulmonary disease)~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 4 weeks after study participation~* No other serious medical or psychiatric conditions~* No active infection~* No serious malabsorption syndromes~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy and recovered~Chemotherapy:~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered~Endocrine therapy:~* Concurrent corticosteroids allowed~Radiotherapy:~* At least 8 weeks since prior radiotherapy (less than 8 weeks if multiple tumors are involved) and recovered~Surgery:~* No prior extensive stomach or intestinal surgery~* Recovered from any prior surgery~Other:~* Prior cytodifferentiating agents allowed~* No prior antineoplaston treatment~* No other concurrent treatment for metastatic lung cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplastons (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ablation Confirmation Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. A patient with at least one soft-tissue liver lesion less than or equal to 5cm undergoing microwave ablation using the NEUWAVE Microwave Ablation System. Note: a patient cannot have more than 3 lesions ablated during the procedure.~2. Intent to use Ablation Confirmation software (any AC software version permitted) during the ablation procedure.~3. Written Informed Consent to voluntarily participate in the study, follow CT scan schedule, and authorize the transfer of his/her data to the Sponsor~4. Patients greater than or equal to 22 years of age~5. Performance status 0-2 (Eastern Cooperative Oncology Group \[ECOG\]) classification~6. Class A or B functional hepatic reserve based on the Child-Pugh score.~7. Lesion must be visualized by non-contrast enhanced CT scan or the patient must tolerate contrast and meet institutional guidelines for contrast use based on glomerular filtration rate (GFR).~Exclusion Criteria:~1. Active bacterial infection or fungal infection on the day of the ablation.~2. Patients with implantable pacemakers or other electronic implants.~3. Platelet count less than 50,000/mm cubed.~4. Patients with uncorrectable coagulopathy at the time of ablation.~5. Currently breastfeeding or pregnant (latter confirmed by serum pregnancy test, per site's SOC).~6. Physical or psychological condition which would impair study participation.~7. ASA (American Society of Anesthesiologists) score of great or equal to 4.~8. Use of hydrodissection.~9. Systemic chemotherapy or radiation therapy for the liver, within 30 days prior to the study ablation procedure.~10. INR greater than 1.8.~11. Patient has participated in an investigational clinical study within 30 days of the screening visit for this study.~12. Patient judged unsuitable for study participation by the performing physician for any other reason.

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Microwave Ablation (Type: EXPERIMENTAL): NEUWAVE Microwave Ablation System with AC software for patients undergoing a percutaneous ablation of a soft tissue liver lesion by an interventional radiologist.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have documentation of histologically or cytologically confirmed metastatic or locally advanced adenocarcinoma of the distal esophagus, GE junction or stomach~* Patients must have documentation of histologically or cytologically confirmed HER2 expression~* Patients must be ≥18 years of age~* Patients must have ECOG PS of 0, 1, or 2~* Patients must have adequate hematologic status, renal and hepatic function~Exclusion Criteria:~* Patients with known hypersensitivity to any of the components of MM-111~* Patients with a known history of hypersensitivity to paclitaxel or other drugs formulated in Cremophor® EL~* Patients with a known history of hypersensitivity to trastuzumab or any of its components (group 1 patients only)~* Patients with an active infection or with an unexplained fever \>38.5°C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1a (Type: EXPERIMENTAL): MM-111 + Paclitaxel + Trastuzumab
- Arm 1b (Type: ACTIVE_COMPARATOR): Paclitaxel + Trastuzumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Propranolol in Capillary Hemangiomas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infant aged less than 4 months~* Infant with one or more hemangiomas sized more than 1 cm diameter~* Infant not threatening for vital or functional structure and for which no treatment would be proposed~* Informed consent~* Patient with social insurance.~Exclusion Criteria:~* Alarming hemangioma (s) (complicated forms or localization at risk)~* Cardiac pathology (cardiac malformation, heart failure, cardiac arrhythmias, pulmonary hypertension)~* Asthma~* Bronchopulmonary dysplasia~* Bronchiolitis~* Raynaud syndrome~* Phéochromocytoma~* Development of serious form of hemangioma (bleeding, necrosis, ulceration, infection, respiratory distress) requiring standard treatment

- Gender: ALL
- Minimum Age: None
- Maximum Age: 4 Months
- Healthy Volunteers: f

Study Arms:
- 2 (Type: PLACEBO_COMPARATOR): 30-days placebo treatment
- 1 (Type: EXPERIMENTAL): 30-days propranolol treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Functional MRI and DTI in the Preoperative Assessment of Dystonia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age limits ≥ 18 et \< 85 years~* Right-handed patients/healthy controls, according to Edinburgh Handedness Inventory~* The participating subjects must be affiliated to the French public health system~* Written consent to participate in this study~For the patients~* Patients affected by isolated or complex dystonia admitted to hospital in the Unit of Functional Neurosurgery in order to assess eligibility for deep cerebral stimulation therapy~* Ability to understand the instructions to perform the experimental paradigm (the motor task) used in the design of the functional MRI~For the healthy control subjects :~* Absence of current neurologic pathology~* Absence of personal history of neurologic pathology, including perinatal anoxic injury, meningitis, vascular, metabolic, inflammatory pathology, epilepsy, cranial trauma with loss of consciousness or with associated neurological symptoms.~* Absence of orthopaedic injury in the upper limbs~Exclusion Criteria:~* Non Specific criteria~  * Contraindication for the realization of a MRI (pacemaker, valve prothesis non compatible with MRI, cochlear implant, aneuvrysmal clip, presence of an Intra-ocular metallic foreign object or coronary endoprosthesis)~ * Pregnancy, breastfeeding~ * Adults protected by the law~* Non Specific criteria • Severe dyskinesia preventing the realization of motor task during functional MRI without general anesthesia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 84 Years
- Healthy Volunteers: t

Study Arms:
- Segmentary dystonia (Type: OTHER): to identify movement-related functional magnetic resonance imaging (fMRI) activation patterns
- Hemidystonia (Type: OTHER): to identify movement-related functional magnetic resonance imaging (fMRI) activation patterns
- Generalized dystonia (Type: OTHER): to identify movement-related functional magnetic resonance imaging (fMRI) activation patterns
- Healthy control subjects (Type: OTHER): to identify movement-related functional magnetic resonance imaging (fMRI) activation patterns

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues